• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲胎蛋白和脱γ-羧基凝血酶原联合检测在肝癌检测中具有优势。

A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.

机构信息

Department of Gastroenterology and Hepatology, University Hospital Essen, Essen, Germany.

出版信息

Digestion. 2013;87(2):121-31. doi: 10.1159/000346080. Epub 2013 Feb 8.

DOI:10.1159/000346080
PMID:23406785
Abstract

BACKGROUND AND AIM

The incidence of hepatocellular carcinoma (HCC) is increasing in western countries. Despite its low sensitivity, the diagnosis of HCC still depends on detection of α-fetoprotein (AFP). Therefore, the aim of this study was to evaluate the combined analysis of AFP and des-γ-carboxy prothrombin (DCP) in a European cohort.

METHODS

We performed a single-center study (164 HCC/422 controls), in which the serum concentrations of AFP and DCP were determined.

RESULTS

AFP and DCP were elevated in HCC patients compared to controls (p < 0.0001). By combination of AFP and DCP, the sensitivity was improved from 28.7% for AFP (cutoff 400 ng/ml; AFP at cutoff 10 ng/ml: 54.9%) to 78.0% using cutoffs of 10 ng/ml for AFP and 5 ng/ml for DCP (DCP alone, cutoff 5 ng/ml: 63.4%). Among early-stage patients, the sensitivity increased from 20% for AFP (cutoff 400 ng/ml; AFP at cutoff 10 ng/ml: 38%) to 55% in combination (DCP alone, cutoff 5 ng/ml: 47%). The area under the curve (AUC) for AFP and DCP was similar (AFP: 0.88; DCP: 0.87; combined: 0.91). Among non-cirrhotic patients, DCP (AUC: 0.93) showed a better performance than AFP (AUC: 0.84). Especially patients with non-alcoholic steatohepatitis had a high percentage of DCP-positive tumors.

CONCLUSION

The data suggest that AFP alone is not sufficient for the serological diagnosis of HCC in European patients, while a combination of AFP and DCP can increase the sensitivity even in early-stage patients.

摘要

背景与目的

在西方国家,肝细胞癌(HCC)的发病率正在增加。尽管 AFP 的灵敏度较低,但 HCC 的诊断仍依赖于 AFP 的检测。因此,本研究旨在评估 AFP 和脱γ-羧基凝血酶原(DCP)联合分析在欧洲队列中的作用。

方法

我们进行了一项单中心研究(164 例 HCC/422 例对照),其中检测了 AFP 和 DCP 的血清浓度。

结果

与对照组相比,HCC 患者的 AFP 和 DCP 水平升高(p<0.0001)。通过 AFP 和 DCP 的联合检测,灵敏度从 AFP 的 28.7%(截断值 400ng/ml;AFP 截断值 10ng/ml:54.9%)提高到 AFP 截断值 10ng/ml 和 DCP 截断值 5ng/ml 的 78.0%(DCP 单独,截断值 5ng/ml:63.4%)。在早期患者中,灵敏度从 AFP 的 20%(截断值 400ng/ml;AFP 截断值 10ng/ml:38%)提高到联合检测的 55%(DCP 单独,截断值 5ng/ml:47%)。AFP 和 DCP 的曲线下面积(AUC)相似(AFP:0.88;DCP:0.87;联合:0.91)。在非肝硬化患者中,DCP(AUC:0.93)的表现优于 AFP(AUC:0.84)。特别是非酒精性脂肪性肝炎患者中 DCP 阳性肿瘤的比例较高。

结论

数据表明,在欧洲患者中,AFP 单独用于 HCC 的血清学诊断并不充分,而 AFP 和 DCP 的联合检测甚至可以提高早期患者的灵敏度。

相似文献

1
A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.甲胎蛋白和脱γ-羧基凝血酶原联合检测在肝癌检测中具有优势。
Digestion. 2013;87(2):121-31. doi: 10.1159/000346080. Epub 2013 Feb 8.
2
Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.慢性肝炎、肝硬化和肝细胞癌患者的去γ-羧基凝血酶原、甲胎蛋白和甲胎蛋白-L3
J Gastroenterol Hepatol. 2008 Oct;23(10):1541-8. doi: 10.1111/j.1440-1746.2008.05395.x. Epub 2008 Apr 19.
3
Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.去γ-羧基凝血酶原对肝细胞癌患者的诊断敏感性和特异性因肿瘤大小而异。
Am J Gastroenterol. 2006 Sep;101(9):2038-43. doi: 10.1111/j.1572-0241.2006.00681.x. Epub 2006 Jul 18.
4
Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.采用高敏电化学发光系统检测血清去γ-羧基凝血酶原水平的序贯波动模式,作为肝硬化患者肝细胞癌的早期预测标志物。
Int J Mol Med. 2002 Mar;9(3):245-50.
5
Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.使用修订的酶免疫测定试剂盒测定的血清去γ-羧基凝血酶原水平,其相对于孤立性肝细胞癌的临床病理特征具有更高的灵敏度。
Cancer. 2000 Feb 1;88(3):544-9.
6
Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.甲胎蛋白和去γ-羧基凝血酶原在接受肝切除术的肝细胞癌患者中的意义。
Ann Surg Oncol. 2009 Oct;16(10):2795-804. doi: 10.1245/s10434-009-0618-y. Epub 2009 Aug 11.
7
Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.单独或联合使用甲胎蛋白的豆凝集素反应性组分和去γ-羧基凝血酶原作为肝细胞癌生物标志物的效用。
Clin Gastroenterol Hepatol. 2009 Jan;7(1):104-13. doi: 10.1016/j.cgh.2008.08.041. Epub 2008 Sep 17.
8
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.去γ羧基凝血酶原可区分美国患者的肝细胞癌与非恶性慢性肝病。
Hepatology. 2003 May;37(5):1114-21. doi: 10.1053/jhep.2003.50195.
9
Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.维生素K缺乏诱导蛋白在肝细胞癌检测中的应用价值
Chin Med J (Engl). 2002 Jan;115(1):42-5.
10
Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.甲胎蛋白、脱 γ-羧基凝血酶原与鳞状细胞癌相关抗原免疫球蛋白 M 复合物在原发性肝癌中的诊断及预后价值。
Minerva Med. 2011 Oct;102(5):363-71.

引用本文的文献

1
Screening and surveillance of hepatocellular carcinoma by serum des-gamma-carboxy prothrombin in patients with glycogen storage disease type Ia.Ia型糖原贮积病患者血清去γ-羧基凝血酶原对肝细胞癌的筛查和监测
JIMD Rep. 2024 May 29;65(4):207-211. doi: 10.1002/jmd2.12414. eCollection 2024 Jul.
2
Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.GALAD 评分在肝细胞癌分期和 1 年死亡率中的诊断和预后性能:一项前瞻性研究。
World J Gastroenterol. 2024 May 7;30(17):2343-2353. doi: 10.3748/wjg.v30.i17.2343.
3
Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study.
PIVKA-II 对识别根治性切除术后复发性肝细胞癌的诊断性能:一项回顾性队列研究。
Sci Rep. 2024 Apr 10;14(1):8416. doi: 10.1038/s41598-024-59174-5.
4
Combination of serum alpha-fetoprotein, PIVKA-Ⅱ and glypican-3 in diagnosis of hepatocellular carcinoma: a meta-analysis.血清甲胎蛋白、异常凝血酶原和磷脂酰肌醇聚糖蛋白 3 联合检测在肝细胞癌诊断中的价值:一项荟萃分析。
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024 Feb 1;53(1):131-139. doi: 10.3724/zdxbyxb-2023-0483.
5
Development and application of hepatocellular carcinoma risk prediction model based on clinical characteristics and liver related indexes.基于临床特征和肝脏相关指标的肝细胞癌风险预测模型的建立与应用
World J Gastrointest Oncol. 2023 Aug 15;15(8):1486-1496. doi: 10.4251/wjgo.v15.i8.1486.
6
Protein Induced by Vitamin K Absence or Antagonist-II Versus Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.维生素K缺乏或拮抗剂-II诱导蛋白与甲胎蛋白在肝细胞癌诊断中的比较:一项Meta分析的系统评价
J Clin Med Res. 2023 Jul;15(7):343-359. doi: 10.14740/jocmr4951. Epub 2023 Jul 12.
7
Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population.甲基化 SEPT9 联合 AFP 和 PIVKA-II 可有效检测高危人群 HCC。
BMC Gastroenterol. 2023 Jul 31;23(1):260. doi: 10.1186/s12876-023-02900-6.
8
Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.非酒精性脂肪性肝病相关肝细胞癌的风险因素和诊断生物标志物:当前证据和未来展望。
World J Gastroenterol. 2022 Jul 21;28(27):3410-3421. doi: 10.3748/wjg.v28.i27.3410.
9
Common Sensitive Diagnostic and Prognostic Markers in Hepatocellular Carcinoma and Their Clinical Significance: A Review.肝细胞癌常见敏感诊断和预后标志物及其临床意义:综述
Cureus. 2022 Apr 8;14(4):e23952. doi: 10.7759/cureus.23952. eCollection 2022 Apr.
10
Serum Anti-14-3-3 Zeta Autoantibody as a Biomarker for Predicting Hepatocarcinogenesis.血清抗14-3-3ζ自身抗体作为预测肝癌发生的生物标志物
Front Oncol. 2021 Oct 15;11:733680. doi: 10.3389/fonc.2021.733680. eCollection 2021.